Compare CWCO & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CWCO | PRME |
|---|---|---|
| Founded | 1973 | 2019 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Water Supply | Medicinal Chemicals and Botanical Products |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 478.2M | 536.4M |
| IPO Year | 1997 | 2022 |
| Metric | CWCO | PRME |
|---|---|---|
| Price | $30.34 | $2.95 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $40.00 | $7.56 |
| AVG Volume (30 Days) | 75.3K | ★ 4.0M |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.73% | N/A |
| EPS Growth | N/A | ★ 18.18 |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $132,073,368.00 | $4,632,000.00 |
| Revenue This Year | $4.34 | $7.06 |
| Revenue Next Year | $42.86 | $47.01 |
| P/E Ratio | $128.35 | ★ N/A |
| Revenue Growth | N/A | ★ 55.28 |
| 52 Week Low | $28.17 | $2.67 |
| 52 Week High | $39.12 | $6.94 |
| Indicator | CWCO | PRME |
|---|---|---|
| Relative Strength Index (RSI) | 62.20 | 40.88 |
| Support Level | $30.09 | $2.68 |
| Resistance Level | $30.69 | $3.68 |
| Average True Range (ATR) | 0.46 | 0.24 |
| MACD | 0.15 | -0.08 |
| Stochastic Oscillator | 88.22 | 7.75 |
Consolidated Water Co Ltd is a water utility company. It develops and operates seawater desalination plants and water distribution systems. The company's business segments are; The retail segment operates the water utility for the Seven Mile Beach and West Bay areas of Grand Cayman Island, The bulk segment supplies potable water to government utilities in Grand Cayman and The Bahamas under long-term contracts, The services segment designs, constructs and sells water infrastructure and provides management and operating services to third parties. The manufacturing segment manufactures and services a wide range of custom and specialized water-related products applicable to commercial, municipal, and industrial water production, supply, and treatment, and the corporate segment.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.